

Immunization Programs and Vaccine Preventable Diseases Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: January 20, 2023 Administrative Circular: 2023:02

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products & Appendix E – Management of Biologicals

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Content has been added for the Moderna Bivalent (Original/Omicron BA.4/5) COVID-19 mRNA vaccine under Fall 2022 Booster Dose. NACI indicates there is currently no evidence to suggest any meaningful difference in protection between different bivalent booster vaccines targeting BA.1 versus BA.4/5.

Please remove page numbers: 1-3 dated January 2023 Please add new page numbers: 1-3 dated January 20, 2023

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) Adult/Adolescent

- ADMINISTRATION: Footnote B on page 2 has been revised to indicate that the vaccine may be used for up to 18 months from the date of manufacture when stored at -90°C to -60°C. Hyperlink to Pfizer Information About Expiry Dates resource will be added once updated.
- PRECAUTIONS: Footnote A on page 4 has been revised to indicate Novavax COVID-19 vaccine may be offered if age-eligible.

Please remove page numbers: 1-6 dated December 9, 2022 Please add new page numbers: 1-6 dated January 2023





COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 years of age

ADMINISTRATION: Footnote B on page 2 has been revised to indicate that the vaccine may be used for up to 18 months from the date of manufacture when stored at -90°C to -60°C. Hyperlink to Pfizer Information About Expiry Dates resource will be added once updated.

> Please remove page numbers: 1-6 dated December 9, 2022 Please add new page numbers: 1-6 dated January 2023

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) 6 months to 4 years of age

ADMINISTRATION: Footnote B on page 2 has been revised to indicate that the vaccine may be used for up to 18 months from the date of manufacture when stored at -90°C to -60°C. Hyperlink to Pfizer Information About Expiry Dates resource will be added once updated.

> Please remove page numbers: 1-5 dated December 9, 2022 Please add new page numbers: 1-5 dated January 2023

COVID-19 mRNA Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) Adult/Adolescent

PRECAUTIONS: Footnote A on page 3 has been revised to indicate Novavax COVID-19 vaccine may be offered if age-eligible.

> Please remove page numbers: 1-4 dated November 4, 2022 Please add new page numbers: 1-4 dated January 2023

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older

PRECAUTIONS: Footnote A on page 3 has been revised to indicate Novavax COVID-19 vaccine may be offered if age-eligible.

> Please remove page numbers: 1-5 dated December 9, 2022 Please add new page numbers: 1-5 dated January 2023





COVID-19 mRNA Vaccine SPIKEVAX Bivalent™ (Moderna) Original/Omicron

PRECAUTIONS: Footnote B on page 2 has been revised to indicate Novavax COVID-19 vaccine may be offered if age-eligible.

Please remove page numbers: 1-4 dated November 4, 2022 Please add new page numbers: 1-4 dated January 2023

COVID-19 mRNA Vaccine SPIKEVAX Bivalent™ (Moderna) Original/Omicron BA.4/5

- A new product page has been developed for Spikevax Bivalent™ (Moderna)
 Original/Omicron BA.4/5.
- This product has a Royal Blue Vial Cap and a Gray Label Border.

Please add new page numbers: 1-4 dated January 2023

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated January 2023, and replace with the enclosed updated Title Page and Table of Contents dated January 20, 2023.

Appendix E – Management of Biologicals

Guidance for Receiving and Handling the Moderna COVID-19 mRNA Vaccine

Content under 'Thaw each vial before use' has been updated to include the Moderna Bivalent Original/Omicron BA.4/5 COVID-19 mRNA vaccine preparation.

Please remove page numbers: 1-4 dated October 11, 2022 Please add new page numbers: 1-4 dated January 2023





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

Medical Director

Immunization Programs and Vaccine Preventable Diseases Service

BC Centre for Disease Control

dite bans

pc:

Provincial Health Officer

Dr. Bonnie Henry

BC Ministry of Health,

Population & Public Health Division:

Brian Sagar

Senior Director Communicable Disease,

Population and Public Health Division

Bernard Achampong

Executive Director,

Public Health, Planning and Prevention,

Population and Public Health Division



